While some studies in TNBC have found that HLA-DR high expression is associated with better DFS [28], high-quality research cohorts with tumor region segmentation and reliable OS data have been lacking, particularly in HER2 + BC [38, 46]. The gene discussed is ERBB2; the disease is breast cancer.